In its application, Lykos describes MDMA as a catalyst for that therapeutic process, Which explains why it been given a lot notice. That is not envisioned to get as much of the maintain-up for other psychedelics, nevertheless. “The rest of us are learning molecules that do not call for the identical degree of therapy,” suggests Kabir Nath, CEO